公开(公告)号：EP2640384A1

公开(公告)日：2013-09-25

申请号：EP11791158.6

申请日：2011-11-18

申请人： Synta Pharmaceuticals Corp.

发明人： BLACKMAN, Ronald, K. ,  VUKOVIC, Vojo

IPC分类号： A61K31/4196 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/502 ,  A61K31/506 ,  A61K31/517 ,  A61K31/395 ,  A61P35/00

CPC分类号： G01N33/5023 ,  A61K31/395 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/502 ,  A61K31/506 ,  A61K31/517 ,  A61K2039/55 ,  C07K16/22 ,  C07K16/2863 ,  C07K16/32 ,  C12Q1/6886

摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.

公开(公告)号：EP2999465A1

公开(公告)日：2016-03-30

申请号：EP14732719.1

申请日：2014-05-20

申请人： Synta Pharmaceuticals Corp.

发明人： VUKOVIC, Vojo

IPC分类号： A61K31/282 ,  A61K31/337 ,  A61K31/4196 ,  A61K31/519 ,  A61K31/704 ,  A61P35/00

CPC分类号： A61K31/4196 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K31/555 ,  A61K31/675 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： Methods of treating certain types of cancer with ganetespib are disclosed. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, and a platinum-containing anticancer agent. Also provided are methods of treating certain types of cancer with p53 mutation by a combination of ganetespib with a taxane derivative, and a platinum- containing anticancer agent. Also provided are methods of treating certain types of cancer with ganetespib in combination with a platinum-containing anticancer agent, and an antimetabolite. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, an anthracycline derivative, and an alkylating antineoplastic agent. Also provided is a pharmaceutical composition comprising ganetespib and one or more other anticancer agents as described above.

公开(公告)号：EP2640372A1

公开(公告)日：2013-09-25

申请号：EP11793609.6

申请日：2011-11-18

申请人： Synta Pharmaceuticals Corp.

发明人： BLACKMAN, Ronald, K. ,  VUKOVIC, Vojo

IPC分类号： A61K31/165 ,  A61P35/00

CPC分类号： A61K31/166 ,  A61K31/165 ,  C12Q1/6886 ,  G01N33/57484

摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of hypoxia in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of lactate dehydrogenase (LDH). The invention also provides methods for treating cancer in a subject by administering an effective amount of elesclomol to the subject, wherein the subject has a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.

公开(公告)号：EP2849853A1

公开(公告)日：2015-03-25

申请号：EP13726935.3

申请日：2013-05-15

申请人： Synta Pharmaceuticals Corp.

发明人： VUKOVIC, Vojo ,  YALCIN, Ilker

IPC分类号： A61P35/00 ,  A61K31/41 ,  A61K31/4196

CPC分类号： G01N33/57484 ,  A61K31/4196 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5091 ,  G01N2333/475 ,  G01N2333/71 ,  G01N2333/90203 ,  G01N2333/904 ,  G01N2333/988 ,  G01N2800/52 ,  G01N2800/7038

摘要： The present invention provides methods for the pre-selection of a subject for therapeutic treatment with an Hsp90 inhibitor based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the pre-selection of a subject for therapeutic treatment with an Hsp90 inhibitor based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an Hsp90 inhibitor to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.

公开(公告)号：EP2790691A1

公开(公告)日：2014-10-22

申请号：EP12806824.4

申请日：2012-12-12

申请人： Synta Pharmaceuticals Corp.

发明人： GUO, Wei ,  VUKOVIC, Vojo

IPC分类号： A61K31/16 ,  A61K31/165 ,  A61K31/337 ,  A61K31/439 ,  A61K31/706

CPC分类号： A61K31/16 ,  A61K31/165 ,  A61K31/337 ,  A61K31/439 ,  A61K31/706 ,  A61K2300/00

摘要： The present invention is a method for treating non-small cell lung cancer in a subject in need thereof, comprising administering to the subject an effective amount of a bis(thiohydrazideamide) compound of formula (I): wherein the variables are defined herein. Furthermore, pharmaceutical compositions, combination therapies, and uses thereof are also provided in the present application.

公开(公告)号：EP2729144A2

公开(公告)日：2014-05-14

申请号：EP12735423.1

申请日：2012-07-09

申请人： Synta Pharmaceuticals Corp.

发明人： EL-HARIRY, Iman ,  PROIA, David ,  VUKOVIC, Vojo

IPC分类号： A61K31/4196 ,  A61K31/4439 ,  A61P35/00

CPC分类号： A61K31/4196 ,  A61K31/337 ,  A61K31/417 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/675 ,  A61K33/24 ,  A61K45/06 ,  C07D403/04 ,  A61K2300/00 ,  A61K31/444

摘要： Methods of treating cancer with a compound of formulae (I) or (la) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (la). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (la); a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.

公开(公告)号：EP2640385A1

公开(公告)日：2013-09-25

申请号：EP11793607.0

申请日：2011-11-18

申请人： Synta Pharmaceuticals Corp.

发明人： BLACKMAN, Ronald, K. ,  VUKOVIC, Vojo

IPC分类号： A61K31/4196 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/502 ,  A61K31/506 ,  A61K31/517 ,  A61K39/395 ,  A61P35/00 ,  A61K31/395

CPC分类号： C07K16/22 ,  A61K31/404 ,  A61K31/436 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/506 ,  A61K31/517 ,  G01N33/57484

摘要： The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.

公开(公告)号：EP2616063A1

公开(公告)日：2013-07-24

申请号：EP11760643.4

申请日：2011-09-13

申请人： Synta Pharmaceuticals Corp.

发明人： VUKOVIC, Vojo ,  TEOFILOVICI, Florentina

IPC分类号： A61K31/404 ,  A61K31/4196 ,  A61K31/423 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K45/06 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/423 ,  A61K2300/00

摘要： Provided is a method for treating non-small cell lung cancer with wild-type EGFR gene and/or KRAS gene by administering to a subject in need thereof, an effective amount of a triazolone compound according to the following formula: ( l ), or ( la ) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein.